Overcoming the limitations of locally administered oncolytic virotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, JinWoo | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2023-09-04T19:26:23Z | - |
dc.date.available | 2023-09-04T19:26:23Z | - |
dc.date.created | 2023-05-30 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 2524-4426 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190230 | - |
dc.description.abstract | Adenovirus (Ad) has been most extensively evaluated gene transfer vector in clinical trials due to facile production inhigh viral titer, highly efficient transduction, and proven safety record. Similarly, an oncolytic Ad, which replicatesselectively in cancer cells through genetic modifications, is actively being evaluated in various phases of clinical trials asa promising next generation therapeutic against cancer. Most of these trials with oncolytic Ads to date have employedintratumoral injection as the standard administration route. Although these locally administered oncolytic Ads haveshown promising outcomes, the therapeutic efficacy is not yet optimal due to poor intratumoral virion retention,nonspecific shedding of virion to normal organs, variable infection efficacy due to heterogeneity of tumor cells,adverse antiviral immune response, and short biological activity of oncolytic viruses in situ. These inherent problemsassociated with locally administered Ad also holds true for other oncolytic viral vectors. Thus, this review will aim todiscuss various nanomaterial-based delivery strategies to improve the intratumoral administration efficacy of oncolyticAd as well as other types of oncolytic viruses. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer Nature | - |
dc.title | Overcoming the limitations of locally administered oncolytic virotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.1186/s42490-019-0016-x | - |
dc.identifier.bibliographicCitation | BMC Biomedical Engineering, v.1, no.17, pp.1 - 11 | - |
dc.relation.isPartOf | BMC Biomedical Engineering | - |
dc.citation.title | BMC Biomedical Engineering | - |
dc.citation.volume | 1 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Oncolytic virus | - |
dc.subject.keywordAuthor | Adenovirus | - |
dc.subject.keywordAuthor | Nanomaterial | - |
dc.subject.keywordAuthor | Local administration | - |
dc.subject.keywordAuthor | Intratumoral injection | - |
dc.subject.keywordAuthor | Polymer | - |
dc.subject.keywordAuthor | Delivery systems | - |
dc.identifier.url | https://bmcbiomedeng.biomedcentral.com/articles/10.1186/s42490-019-0016-x | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.